$MTEM
Molecular Templates, Inc.

2017 Q1 Form 10-K Financial Statement

#000156459017005351 Filed on March 27, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q4 2015 Q4
Revenue $1.885M $0.00 $65.87M
YoY Change -100.0% 1689.95%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.790M $1.950M $2.250M
YoY Change -20.44% -13.33% -14.12%
% of Gross Profit
Research & Development $1.070M $3.010M $11.37M
YoY Change -82.18% -73.53% 32.06%
% of Gross Profit
Depreciation & Amortization $18.00K $20.00K $250.0K
YoY Change -90.53% -92.0% -10.71%
% of Gross Profit
Operating Expenses $2.858M $4.960M $13.62M
YoY Change -65.37% -63.58% 21.28%
Operating Profit -$973.0K
YoY Change -88.21%
Interest Expense $223.0K $40.00K $30.00K
YoY Change 596.88% 33.33% 50.0%
% of Operating Profit
Other Income/Expense, Net $1.250M $17.43M
YoY Change -92.83% 1017.31%
Pretax Income -$1.200M -$3.680M $69.71M
YoY Change -84.71% -105.28% -1269.63%
Income Tax $0.00
% Of Pretax Income 0.0%
Net Earnings -$1.200M -$3.682M $69.71M
YoY Change -84.72% -105.28% -1268.9%
Net Earnings / Revenue -63.66% 105.83%
Basic Earnings Per Share -$0.05 $0.98
Diluted Earnings Per Share -$5.714M -$0.05 $0.86
COMMON SHARES
Basic Shares Outstanding 71.59M 71.56M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q4 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.60M $1.700M $48.70M
YoY Change -53.68% -96.51% -16.89%
Cash & Equivalents $2.940M $1.716M $4.245M
Short-Term Investments $6.200M $39.10M
Other Short-Term Assets $400.0K $7.000K $2.600M
YoY Change -78.95% -99.73% 225.0%
Inventory
Prepaid Expenses $120.0K
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $20.00M $1.843M $53.17M
YoY Change -50.74% -96.53% -20.26%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $334.0K $333.0K
YoY Change -100.0% 0.3% -40.22%
Goodwill $0.00
YoY Change
Intangibles $921.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $166.0K
YoY Change -100.0% -85.68%
Total Long-Term Assets $0.00 $22.44M $499.0K
YoY Change -100.0% 4396.99% -70.92%
TOTAL ASSETS
Total Short-Term Assets $20.00M $1.843M $53.17M
Total Long-Term Assets $0.00 $22.44M $499.0K
Total Assets $20.00M $24.28M $53.67M
YoY Change -51.34% -54.75% -21.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $300.0K $822.0K $725.0K
YoY Change -81.25% 13.38% -65.04%
Accrued Expenses $1.900M $888.0K $3.269M
YoY Change -52.5% -72.84% 2.8%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $7.300M $0.00
YoY Change
Long-Term Debt Due $2.400M
YoY Change
Total Short-Term Liabilities $2.200M $13.77M $10.83M
YoY Change -60.54% 27.12% -58.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $3.165M $0.00
YoY Change
Other Long-Term Liabilities $2.400M $53.00K $2.000M
YoY Change 50.0% -97.35% -96.99%
Total Long-Term Liabilities $2.400M $3.218M $2.000M
YoY Change 50.0% 60.9% -96.99%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.200M $13.77M $10.83M
Total Long-Term Liabilities $2.400M $3.218M $2.000M
Total Liabilities $4.600M $17.03M $12.82M
YoY Change -35.92% 32.82% -86.12%
SHAREHOLDERS EQUITY
Retained Earnings -$40.37M -$329.4M
YoY Change -87.74% -11.74%
Common Stock $568.0K $370.3M
YoY Change -99.85% 6.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.30M -$39.81M -$27.32M
YoY Change
Total Liabilities & Shareholders Equity $20.00M $3.098M $53.67M
YoY Change -51.28% -94.23% -21.53%

Cashflow Statement

Concept 2017 Q1 2016 Q4 2015 Q4
OPERATING ACTIVITIES
Net Income -$1.200M -$3.682M $69.71M
YoY Change -84.72% -105.28% -1268.9%
Depreciation, Depletion And Amortization $18.00K $20.00K $250.0K
YoY Change -90.53% -92.0% -10.71%
Cash From Operating Activities -$2.650M -$830.0K -$7.570M
YoY Change -75.07% -89.04% -25.27%
INVESTING ACTIVITIES
Capital Expenditures $8.000K -$70.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$190.0K -$220.0K $3.420M
YoY Change -101.55% -106.43% -50.29%
Cash From Investing Activities -$200.0K -$290.0K $3.420M
YoY Change -101.63% -108.48% -50.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $7.000K
YoY Change -46.15%
Debt Paid & Issued, Net $600.0K
YoY Change
Cash From Financing Activities 4.070M 1.210M 30.00K
YoY Change 40600.0% 3933.33% -92.68%
NET CHANGE
Cash From Operating Activities -2.650M -830.0K -7.570M
Cash From Investing Activities -200.0K -290.0K 3.420M
Cash From Financing Activities 4.070M 1.210M 30.00K
Net Change In Cash 1.220M 90.00K -4.120M
YoY Change -24.69% -102.18% 44.56%
FREE CASH FLOW
Cash From Operating Activities -$2.650M -$830.0K -$7.570M
Capital Expenditures $8.000K -$70.00K $0.00
Free Cash Flow -$2.658M -$760.0K -$7.570M
YoY Change -75.0% -89.96% -25.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
71000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
370236000
CY2015Q4 us-gaap Liabilities
Liabilities
12823000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
888000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
6801000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
5488000
CY2015 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-14000
CY2014 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
3000
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q2 dei Entity Public Float
EntityPublicFloat
42546096
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
71591918
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9589000
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
39091000
CY2015Q4 thld Collaboration Receivable
CollaborationReceivable
1891000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2599000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
53170000
CY2016Q4 thld Collaboration Payable
CollaborationPayable
129000
CY2015Q4 thld Collaboration Payable
CollaborationPayable
0
CY2016Q4 thld Accrued Clinical And Development Liabilities
AccruedClinicalAndDevelopmentLiabilities
777000
CY2015Q4 thld Accrued Clinical And Development Liabilities
AccruedClinicalAndDevelopmentLiabilities
6834000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3269000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
131000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
89000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
109000
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 dei Trading Symbol
TradingSymbol
THLD
CY2016 dei Entity Registrant Name
EntityRegistrantName
THRESHOLD PHARMACEUTICALS INC
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001183765
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-23976000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-329440000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
40846000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53669000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-21000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71462059
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71462059
CY2014 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
686000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5488000
CY2014 thld Reclassification Of Fair Value Of Warrants Exercised From Liability To Equity
ReclassificationOfFairValueOfWarrantsExercisedFromLiabilityToEquity
10116000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-23475000
CY2014 thld Exercise Of Warrants To Purchase Value Of Class Common Stock
ExerciseOfWarrantsToPurchaseValueOfClassCommonStock
4834000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13453000
CY2015 thld Exercise Of Warrants To Purchase Value Of Class Common Stock
ExerciseOfWarrantsToPurchaseValueOfClassCommonStock
25000
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
712000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6801000
CY2015 thld Reclassification Of Fair Value Of Warrants Exercised From Liability To Equity
ReclassificationOfFairValueOfWarrantsExercisedFromLiabilityToEquity
17000
CY2015 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1900000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
423000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1002000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1309000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
3089000
CY2016 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
121000
CY2015 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
16773000
CY2014 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
9344000
CY2016 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
122000
CY2016 thld Increase Decrease In Receivables Or Payables From Collaboration Partners
IncreaseDecreaseInReceivablesOrPayablesFromCollaborationPartners
-2020000
CY2015 thld Increase Decrease In Receivables Or Payables From Collaboration Partners
IncreaseDecreaseInReceivablesOrPayablesFromCollaborationPartners
-5357000
CY2014 thld Increase Decrease In Receivables Or Payables From Collaboration Partners
IncreaseDecreaseInReceivablesOrPayablesFromCollaborationPartners
-10846000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2142000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
774000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
97000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1349000
CY2016 thld Increase Decrease In Accrued Clinical And Development Liabilities
IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities
-6057000
CY2015 thld Increase Decrease In Accrued Clinical And Development Liabilities
IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities
836000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2381000
CY2016 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
95000
CY2015 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
112000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-76916000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-25099000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-38003000
CY2016 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
17448000
CY2015 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
56793000
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
131000
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2016 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2015Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
48510000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
13002000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2014 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2015 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2014 thld Realized Gains Losses From Unrealized Gains Losses Comprehensive Income
RealizedGainsLossesFromUnrealizedGainsLossesComprehensiveIncome
0
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-5703000
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-3177000
CY2016Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
23217000
CY2016 thld Weighted Average Maturity For Available For Sale Securities
WeightedAverageMaturityForAvailableForSaleSecurities
P1M21D
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
5388000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
3000
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8300000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2949000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2616000
CY2015Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
593000
CY2016Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
0
CY2015Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
2280000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1156704
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
260000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
260000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
800000
CY2016 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
300000
CY2014Q3 thld Aggregate Offering Price Of Common Stock
AggregateOfferingPriceOfCommonStock
30000000
CY2015Q4 thld Aggregate Offering Price Of Common Stock
AggregateOfferingPriceOfCommonStock
50000000
CY2015Q4 thld Aggregate Commission Rate On Gross Proceeds For Common Stock Sold
AggregateCommissionRateOnGrossProceedsForCommonStockSold
0.030
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8300000
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
8300000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28100000
CY2015Q1 thld Warrants Initial Exercise Price
WarrantsInitialExercisePrice
10.86
CY2015Q1 thld Warrant Term
WarrantTerm
P5Y
CY2016Q1 thld Exercise Price Of Warrants Adjusted
ExercisePriceOfWarrantsAdjusted
3.62
CY2016Q1 thld Warrant Minimum Adjusted Exercise Price
WarrantMinimumAdjustedExercisePrice
3.62
CY2016Q1 thld Warrant Maximum Adjusted Exercise Price
WarrantMaximumAdjustedExercisePrice
10.86
CY2016Q1 thld Warrants Twenty Day Vwap Exceeds
WarrantsTwentyDayVWAPExceeds
18.00
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
175236
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
7250000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1286025
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
1895250
CY2014 thld Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
2290500
CY2015 thld Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised
0
CY2015 us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
1327547
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3460540
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
0
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
3072500
CY2016 us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
1156704
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1544744
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6526506
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1895250
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
73282
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
179532
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8168942
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2290500
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
99759
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1327547
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9032136
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3072500
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
6187
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10941745
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.66
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.36
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.78
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.43
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.63
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.69
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.75
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.39
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.77
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.53
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.53
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.50
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.00
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
10900000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
13000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y4M24D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.00
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
400000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
CY2016 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
CY2015 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
CY2014 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
CY2016 thld Share Based Compensation Arrangement By Share Based Payment Award Offering Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
P24M
CY2016 thld Employee Stock Purchase Plan Purchase Period
EmployeeStockPurchasePlanPurchasePeriod
P6M
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.85
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3089000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6801000
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3500000
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2016 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
6000
CY2015 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
100000
CY2014 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
100000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8192000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
14900000
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7407000
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-261000
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-448000
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-571000
CY2016 thld Income Tax Reconciliation Unutilized Utilized Net Operating Losses
IncomeTaxReconciliationUnutilizedUtilizedNetOperatingLosses
7238000
CY2015 thld Income Tax Reconciliation Unutilized Utilized Net Operating Losses
IncomeTaxReconciliationUnutilizedUtilizedNetOperatingLosses
-11287000
CY2014 thld Income Tax Reconciliation Unutilized Utilized Net Operating Losses
IncomeTaxReconciliationUnutilizedUtilizedNetOperatingLosses
9809000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
393000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
898000
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
730000
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1552000
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
3135000
CY2014 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
952000
CY2016 thld Income Tax Reconciliation Tax Assets Not Benefited
IncomeTaxReconciliationTaxAssetsNotBenefited
2398000
CY2015 thld Income Tax Reconciliation Tax Assets Not Benefited
IncomeTaxReconciliationTaxAssetsNotBenefited
4732000
CY2014 thld Income Tax Reconciliation Tax Assets Not Benefited
IncomeTaxReconciliationTaxAssetsNotBenefited
1322000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-41000
CY2015Q4 us-gaap Contracts Revenue
ContractsRevenue
65874000
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
17000
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
43000
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
44000
CY2016Q4 thld Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
78000
CY2015Q4 thld Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
103000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
54250000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
47725000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
13761000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11354000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5191000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5130000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
362000
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
359000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-11154000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-8306000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-6431000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
69713000
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
73642000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
64671000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
64671000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2016Q4 thld Net Operating Loss Deferred Tax Asset From Excess Benefits From Stock Option Exercises
NetOperatingLossDeferredTaxAssetFromExcessBenefitsFromStockOptionExercises
500000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-6200000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9000000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7800000
CY2016 thld Unrecognized Tax Benefits Increases Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions
0
CY2016 thld Unrecognized Tax Benefits Increases Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromCurrentPeriodTaxPositions
0
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2016 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1100000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1100000
CY2015 thld Unrecognized Tax Benefits Increases Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions
0
CY2015 thld Unrecognized Tax Benefits Increases Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromCurrentPeriodTaxPositions
0
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2015 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2016Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2015Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Contracts Revenue
ContractsRevenue
0
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-3682000
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2015Q1 us-gaap Contracts Revenue
ContractsRevenue
3681000
CY2015Q2 us-gaap Contracts Revenue
ContractsRevenue
3680000
CY2015Q3 us-gaap Contracts Revenue
ContractsRevenue
3680000
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2015Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.86
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2015Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.98
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17

Files In Submission

Name View Source Status
0001564590-17-005351-index-headers.html Edgar Link pending
0001564590-17-005351-index.html Edgar Link pending
0001564590-17-005351.txt Edgar Link pending
0001564590-17-005351-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2017032718140340452513.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
thld-10k_20161231.htm Edgar Link pending
thld-20161231.xml Edgar Link completed
thld-20161231.xsd Edgar Link pending
thld-20161231_cal.xml Edgar Link unprocessable
thld-20161231_def.xml Edgar Link unprocessable
thld-20161231_lab.xml Edgar Link unprocessable
thld-20161231_pre.xml Edgar Link unprocessable
thld-ex121_11.htm Edgar Link pending
thld-ex231_7.htm Edgar Link pending
thld-ex311_9.htm Edgar Link pending
thld-ex312_10.htm Edgar Link pending
thld-ex321_8.htm Edgar Link pending
thld-ex322_6.htm Edgar Link pending